脉冲类固醇治疗严重急性呼吸困扰综合征:一个倾向性得分匹配分析
Yasumasa Kawano1,2, Junichi Maruyama2, Mitsuaki Nishikimi3
1Department of Emergency and General Medicine, Fukuoka University Chikushi Hospital, Chikusino 818-8502, Japan.
Journal of clinical medicine
|August 14, 2025
概括
高剂量脉冲类固醇治疗没有改善严重急性呼吸困扰综合征 (ARDS) 患者在毒性体外膜氧化 (ECMO) 的结果. 这项研究发现脉冲和非脉冲类固醇组之间的死亡率或ECMO无天没有显著差异.
科学领域:
- 关键护理医学 关键护理医学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 低剂量的皮质类固醇越来越多地用于急性呼吸困扰综合征 (ARDS).
- 高剂量脉冲类固醇治疗ARDS的有效性仍然不确定.
- 需要静脉 (V-V) 外体膜氧化 (ECMO) 的严重ARDS患者可能受益于增强的抗炎作用.
研究的目的:
- 评估脉冲类固醇治疗在V-V ECMO治疗严重ARDS患者的疗效.
- 为了比较脉冲和非脉冲类固醇治疗组之间的全因医院死亡率和ECMO无天.
主要方法:
- 对J-CARVE注册表 (2012-2022) 的回顾性分析,涉及373名在V-V ECMO接受皮质类固醇治疗的严重ARDS患者.
- 倾向性得分匹配创造了两个组:脉冲类固醇治疗 (甲基普雷迪尼索隆1000毫克/天) 和非脉冲类固醇治疗.
- 所有原因的医院死亡率和28天的ECMO无天的比较.
主要成果:
- 在匹配后,每组都有48名患者.
- 所有原因的医院死亡率在脉冲组为41.7%,而非脉冲组为47.9% (OR,1.28;95%CI:0.53-3.12;p=0.68),没有显著差异.
- 在脉冲组中,无ECMO日的中位数为9.5 (IQR:0-17.3),而在非脉冲组中为3 (IQR:0-17) (p=0.69),也没有显著差异.
结论:
- 脉冲类固醇治疗没有显示出在减少V-V ECMO重症ARDS患者全因住院死亡率方面有显著的益处.
- 在这个患者群体中,28天内的ECMO无天并没有通过脉冲类固醇治疗显著改善.
- 这些发现表明,高剂量脉冲类固醇治疗可能对需要V-V ECMO的严重ARDS患者没有好处.
更多相关视频
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
310
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
310
Acute Respiratory Failure-II
362
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
362
Acute Respiratory Failure-V
208
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
208
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
387
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
387
Acute Respiratory Failure-III
319
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
319
Acute Respiratory Failure-I
327
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
327


